Sandhya R Panch1, Yu Ying Yau2, Courtney D Fitzhugh1,3, Matthew M Hsieh1,3, John F Tisdale1,3, Susan F Leitman2. 1. Hematology/Transfusion Medicine, National Heart, Lung and Blood Institute, Bethesda, Maryland. 2. Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland. 3. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
Abstract
BACKGROUND: Granulocyte-colony-stimulating factor (G-CSF)-stimulated hematopoietic progenitor cells (HPCs) collected by apheresis have become the predominant graft source for HPC transplantation in adults. Among healthy allogeneic donors, demographic characteristics (age, sex, body mass index [BMI]) and baseline hematologic counts affect HPC mobilization, leading to variability in CD34+ apheresis yields. Racial differences in HPC mobilization are less well characterized. STUDY DESIGN AND METHODS: We retrospectively analyzed data from 1096 consecutive G-CSF-stimulated leukapheresis procedures in healthy allogeneic African American (AA) or Caucasian donors. RESULTS: In a multivariate analysis, after adjusting for age, sex, BMI, baseline platelet and mononuclear cell counts, and daily G-CSF dose, peak CD34+ cell mobilization was significantly higher among AAs (n = 215) than Caucasians (n = 881; 123 ± 87 × 10(6) cells/L vs. 75 ± 47 × 10(6) cells/L; p < 0.0001). A ceiling effect was observed with increasing G-CSF dose (10 µg/kg/day vs. 16 µg/kg/day) in AAs (123 ± 88 × 10(6) cells/L vs. 123 ± 87 × 10(6) cells/L) but not in Caucasians (74 ± 46 × 10(6) cells/L vs. 93 ± 53 × 10(6) cells/L; p < 0.001). In AA donors, the presence of sickle cell trait (SCT; n = 41) did not affect CD34+ mobilization (peak CD34+ 123 ± 91 × 10(6) cells/L vs. 107 ± 72 × 10(6) cells/L, HbAS vs. HbAA; p = 0.34). Adverse events were minimal and similar across race. CONCLUSIONS: AAs demonstrated significantly better CD34 mobilization responses to G-CSF than Caucasians. This was independent of other demographic and hematologic variables. Studying race-associated pharmacogenomics in relation to G-CSF may improve dosing strategies. Adverse event profile and CD34 mobilization were similar in AA donors with and without SCT. Our findings suggest that it would be safe to include healthy AA donors with SCT in unrelated donor registries.
BACKGROUND:Granulocyte-colony-stimulating factor (G-CSF)-stimulated hematopoietic progenitor cells (HPCs) collected by apheresis have become the predominant graft source for HPC transplantation in adults. Among healthy allogeneic donors, demographic characteristics (age, sex, body mass index [BMI]) and baseline hematologic counts affect HPC mobilization, leading to variability in CD34+ apheresis yields. Racial differences in HPC mobilization are less well characterized. STUDY DESIGN AND METHODS: We retrospectively analyzed data from 1096 consecutive G-CSF-stimulated leukapheresis procedures in healthy allogeneic African American (AA) or Caucasian donors. RESULTS: In a multivariate analysis, after adjusting for age, sex, BMI, baseline platelet and mononuclear cell counts, and daily G-CSF dose, peak CD34+ cell mobilization was significantly higher among AAs (n = 215) than Caucasians (n = 881; 123 ± 87 × 10(6) cells/L vs. 75 ± 47 × 10(6) cells/L; p < 0.0001). A ceiling effect was observed with increasing G-CSF dose (10 µg/kg/day vs. 16 µg/kg/day) in AAs (123 ± 88 × 10(6) cells/L vs. 123 ± 87 × 10(6) cells/L) but not in Caucasians (74 ± 46 × 10(6) cells/L vs. 93 ± 53 × 10(6) cells/L; p < 0.001). In AA donors, the presence of sickle cell trait (SCT; n = 41) did not affect CD34+ mobilization (peak CD34+ 123 ± 91 × 10(6) cells/L vs. 107 ± 72 × 10(6) cells/L, HbAS vs. HbAA; p = 0.34). Adverse events were minimal and similar across race. CONCLUSIONS: AAs demonstrated significantly better CD34 mobilization responses to G-CSF than Caucasians. This was independent of other demographic and hematologic variables. Studying race-associated pharmacogenomics in relation to G-CSF may improve dosing strategies. Adverse event profile and CD34 mobilization were similar in AA donors with and without SCT. Our findings suggest that it would be safe to include healthy AA donors with SCT in unrelated donor registries.
Authors: Matthew M Hsieh; James E Everhart; Danita D Byrd-Holt; John F Tisdale; Griffin P Rodgers Journal: Ann Intern Med Date: 2007-04-03 Impact factor: 25.391
Authors: Jack W Hsu; John R Wingard; Brent R Logan; Pintip Chitphakdithai; Gorgun Akpek; Paolo Anderlini; Andrew S Artz; Chris Bredeson; Steven Goldstein; Gregory Hale; Peiman Hematti; Sarita Joshi; Rammurti T Kamble; Hillard M Lazarus; Paul V O'Donnell; Michael A Pulsipher; Bipin N Savani; Raquel M Schears; Bronwen E Shaw; Dennis L Confer Journal: Biol Blood Marrow Transplant Date: 2014-10-12 Impact factor: 5.742
Authors: Alison R Moliterno; Donna M Williams; Laura I Gutierrez-Alamillo; Roberto Salvatori; Roxann G Ingersoll; Jerry L Spivak Journal: Proc Natl Acad Sci U S A Date: 2004-07-21 Impact factor: 11.205
Authors: Michael A Pulsipher; Pintip Chitphakdithai; Brent R Logan; Bronwen E Shaw; John R Wingard; Hillard M Lazarus; Edmund K Waller; Matthew Seftel; David F Stroncek; Angela M Lopez; Dipnarine Maharaj; Peiman Hematti; Paul V O'Donnell; Alison W Loren; Susan F Leitman; Paolo Anderlini; Steven C Goldstein; John E Levine; Willis H Navarro; John P Miller; Dennis L Confer Journal: Blood Date: 2012-10-29 Impact factor: 22.113
Authors: Gregory M T Guilcher; Tony H Truong; Santosh L Saraf; Jacinth J Joseph; Damiano Rondelli; Matthew M Hsieh Journal: Semin Hematol Date: 2018-04-25 Impact factor: 3.851
Authors: David F Stroncek; Bronwen E Shaw; Brent R Logan; Deidre M Kiefer; Bipin N Savani; Paolo Anderlini; Christopher N Bredeson; Peiman Hematti; Siddhartha Ganguly; Miguel Angel Diaz; Hisham Abdel-Azim; Ibrahim Ahmed; Dipnarine Maharaj; Matthew Seftel; Amer Beitinjaneh; Sachiko Seo; Jean A Yared; Joerg Halter; Paul V O'Donnell; Gregory A Hale; Zachariah DeFilipp; Hillard Lazarus; Jane L Liesveld; Zheng Zhou; Pashna Munshi; Richard F Olsson; Kimberly Anne Kasow; Jeffrey Szer; Galen E Switzer; Pintip Chitphakdithai; Nirali Shah; Dennis L Confer; Michael A Pulsipher Journal: Biol Blood Marrow Transplant Date: 2017-09-25 Impact factor: 5.742
Authors: Sandhya R Panch; Brent Logan; Jennifer A Sees; Stephanie Bo-Subait; Bipin Savani; Nirali N Shah; Jack W Hsu; Galen Switzer; Hillard M Lazarus; Paolo Anderlini; Peiman Hematti; Dennis Confer; Michael A Pulsipher; Bronwen E Shaw; David F Stroncek Journal: Transplant Cell Ther Date: 2021-03-09
Authors: Bashira A Charles; Matthew M Hsieh; Adebowale A Adeyemo; Daniel Shriner; Edward Ramos; Kyung Chin; Kshitij Srivastava; Neil A Zakai; Mary Cushman; Leslie A McClure; Virginia Howard; Willy A Flegel; Charles N Rotimi; Griffin P Rodgers Journal: PLoS One Date: 2018-03-29 Impact factor: 3.240